Ziftomenib: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Ziftomenib. Educational only — not medical advice.

Labeled uses

KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1 ) mutation who have no satisfactory alternative treatment options [see Dosage and Administration (2.1 ), Clinical Pharmacology (12.1 ), and Clinical Studies (14 )] .

Source: FDA labeling via NIH DailyMed (set b650f696…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.